The DOI matches its Crossref record.
Dose Response Effect of High‐Dose Fluconazole for HIV‐Associated Cryptococcal Meningitis in Southwestern Uganda
Abstract
BACKGROUND: Therapy for human immunodeficiency virus (HIV)-associated cryptococcal meningitis in many centers in Africa is fluconazole administered at a dosage of 400-800 mg per day. However, higher dosages of fluconazole have been used to treat patients without resulting in serious toxicity. Pharmacokinetic and pharmacodynamic considerations suggest that higher dosages might be associated with greater efficacy. METHODS: Sixty HIV-seropositive, antiretroviral therapy-naive patients with first-episode cryptococcal meningitis in Mbarara, Uganda, were treated with fluconazole: the first 30 patients received 800 mg per day, and the second 30 patients received 1200 mg per day. After 2 weeks, the dosage was reduced to 400 mg per day for an additional 8 weeks. The primary outcome measure was rate of clearance of infection, or early fungicidal activity, as determined by serial quantitative cerebrospinal fluid cryptococcal cultures during the first 2 weeks. Secondary outcome measures were safety and mortality through 10 weeks. RESULTS: Forty-seven percent of patients had a reduced level of consciousness at presentation. Early fungicidal activity was significantly greater for patients receiving fluconazole at a dosage of 1200 mg per day than it was for patients receiving 800 mg per day (early fungicidal activity +/- standard deviation, -0.18+/-0.11 vs. -0.07+/-0.17 log colony-forming units/mL per day; P=.007). Fluconazole administered at a dosage of 1200 mg per day appeared to be well tolerated, and no liver function disturbance was observed. Two-week and 10-week mortality were 30% and 54%, respectively, with no statistically significant difference between the groups. CONCLUSIONS: Fluconazole is more rapidly fungicidal when administered at a dosage of 1200 mg per day than when administered at a dosage of 800 mg per day. In resource-limited settings, additional studies are needed to test the addition of flucytosine or short-duration amphotericin B to high-dose fluconazole and to test strategies to facilitate earlier presentation, diagnosis, and treatment of patients with cryptococcal meningitis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Perfect, J. R., Dismukes, W. E., Dromer, F., Goldman, D. L., Graybill, J. R., Hamill, R. J., Harrison, T. S., Larsen, R. A., Lortholary, O., Nguyen, M.-H., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/649858 · Cited by 2,660
Self-citationCombination Antifungal Therapy for Cryptococcal Meningitis
Day, J. N., Chau, T. T. H., Wolbers, M., Mai, P. P., Dung, N. T., Mai, N. H., Phu, N. H., Nghia, H. D., Phong, N. D., Thai, C. Q., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1110404 · Cited by 545
Timing of Antiretroviral Therapy after Diagnosis of Cryptococcal Meningitis
Boulware, D. R., Meya, D. B., Muzoora, C., Rolfes, M. A., Huppler Hullsiek, K., Musubire, A., Taseera, K., Nabeta, H. W., Schutz, C., Williams, D. A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312884 · Cited by 497
Self-citationCryptococcal meningitis: epidemiology, immunology, diagnosis and therapy
Williamson, P. R., Jarvis, J. N., Panackal, A. A., Fisher, M. C., Molloy, S. F., Loyse, A., & Harrison, T. S. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.167 · Cited by 480
Self-citationAntifungal Combinations for Treatment of Cryptococcal Meningitis in Africa
Molloy, S. F., Kanyama, C., Heyderman, R. S., Loyse, A., Kouanfack, C., Chanda, D., Mfinanga, S., Temfack, E., Lakhi, S., Lesikari, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1710922 · Cited by 396
Self-citationJarvis, J. N., Bicanic, T., Loyse, A., Namarika, D., Jackson, A., Nussbaum, J. C., Longley, N., Muzoora, C., Phulusa, J., Taseera, K., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/cit794 · Cited by 367
Self-citationChang, C. C., Harrison, T. S., Bicanic, T. A., Chayakulkeeree, M., Sorrell, T. C., Warris, A., Hagen, F., Spec, A., Oladele, R., Govender, N. P., et al. (2024) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(23)00731-4 · Cited by 326
Self-citationTherapy for fungal diseases: opportunities and priorities
Denning, D. W., & Hope, W. W. (2010) · Trends in Microbiology · doi:10.1016/j.tim.2010.02.004 · Cited by 314
Haddow, L. J., Colebunders, R., Meintjes, G., Lawn, S. D., Elliott, J. H., Manabe, Y. C., Bohjanen, P. R., Sungkanuparph, S., Easterbrook, P. J., French, M. A., et al. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70170-5 · Cited by 302
Meya, D. B., Manabe, Y. C., Castelnuovo, B., Cook, B. A., Elbireer, A. M., Kambugu, A., Kamya, M. R., Bohjanen, P. R., & Boulware, D. R. (2010) · Clinical Infectious Diseases · doi:10.1086/655143 · Cited by 296
Cryptococcal meningitis: epidemiology and therapeutic options
Sloan, D., & Parris, V. (2014) · Clinical Epidemiology · doi:10.2147/clep.s38850 · Cited by 277
Bicanic, T., Muzoora, C., Brouwer, A. E., Meintjes, G., Longley, N., Taseera, K., Rebe, K., Loyse, A., Jarvis, J., Bekker, L., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/604716 · Cited by 227
Self-citationRhein, J., Morawski, B. M., Hullsiek, K. H., Nabeta, H. W., Kiggundu, R., Tugume, L., Musubire, A., Akampurira, A., Smith, K. D., Alhadab, A., et al. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)00074-8 · Cited by 183
Dynamic ploidy changes drive fluconazole resistance in human cryptococcal meningitis
Stone, N. R. H., Rhodes, J., Fisher, M. C., Mfinanga, S., Kivuyo, S., Rugemalila, J., Segal, E. S., Needleman, L., Molloy, S. F., Kwon-Chung, J., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci124516 · Cited by 167
Self-citationRhodes, J., Beale, M. A., Vanhove, M., Jarvis, J. N., Kannambath, S., Simpson, J. A., Ryan, A., Meintjes, G., Harrison, T. S., Fisher, M. C., et al. (2017) · G3 Genes|Genomes|Genetics · doi:10.1534/g3.116.037499 · Cited by 100
Self-citationJackson, A. T., Nussbaum, J. C., Phulusa, J., Namarika, D., Chikasema, M., Kanyemba, C., Jarvis, J. N., Jaffar, S., Hosseinipour, M. C., van der Horst, C., et al. (2012) · AIDS · doi:10.1097/qad.0b013e328354b419 · Cited by 86
Self-citationJarvis, J. N., Leeme, T. B., Molefi, M., Chofle, A. A., Bidwell, G., Tsholo, K., Tlhako, N., Mawoko, N., Patel, R. K. K., Tenforde, M. W., et al. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciy515 · Cited by 86
Self-citationHope, W., Stone, N. R. H., Johnson, A., McEntee, L., Farrington, N., Santoro-Castelazo, A., Liu, X., Lucaci, A., Hughes, M., Oliver, J. D., et al. (2019) · mBio · doi:10.1128/mbio.02575-19 · Cited by 70
Self-citationParkes‐Ratanshi, R., Achan, B., Kwizera, R., Kambugu, A., Meya, D., & Denning, D. W. (2015) · Mycoses · doi:10.1111/myc.12387 · Cited by 49
Huang, Y., Zhang, Y., Yang, S., Lu, H., Yu, H., Wang, X., Jia, X., Tang, D., Wu, L., Huang, S., et al. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.00725-24 · Cited by 12
Novel ABC Transporter Associated with Fluconazole Resistance in Aging of Cryptococcus neoformans
Oliveira, N. K., Bhattacharya, S., Gambhir, R., Joshi, M., & Fries, B. C. (2022) · doi:10.20944/preprints202201.0263.v1 · Cited by 24
Metadata
- Authors
- Longley, N., Muzoora, C., Taseera, K., Mwesigye, J., Rwebembera, J., Chakera, A., Wall, E., Andia, I., Jaffar, S., & Harrison, T. S.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-12-15
- Volume
- 47
- Issue
- 12
- Pages
- 1556-1561
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2150702714
- Cited by
- 202
- References
- 0
- FWCI
- 9.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.